Joining forces to grow the EU biomedical ecosystem
Crystal Bio Solutions, a member of Crystal Pharmatech
Your Global Partner for Analytical, Bioanalytical & QCP Innovation.
Positive Governmental support in Belgium is encouraging for further pharma expansion
At a recent private meeting between Amador Bioscience and the Ambassador of Belgium to the United States Jean-Arthur Régibeau, the Ambassador said: “Innovative companies like Amador are very welcome in Belgium. The company is a good fit for the ecosystem, with plenty of opportunities for collaboration in the field of new drug development.”
The comment is emblematic of the warm welcome Amador has received since opening its first European base in Belgium. The meeting with the Ambassador, which also included Ralph Moreau (Science & Technology Counselor - Climate Tech - for The Americas, at Flanders Investment & Trade (FIT) ), Ms. Xiaomin Chen (Amador COO), and Dr. Meina Liang (Amador CTO), demonstrated the mutual commitment to strengthening the Belgian Pharma Ecosystem.
“The Amador team is excited to collaborate with the highly supportive Belgian government, to further enhance the high-quality clinical development ecosystem in the region,” says Xiaomin Chen.
Amador, which already had branches in the United States and China, was attracted specifically to the Health Campus in Hasselt, Limburg, due to the proximity of the Hasselt University, which has a strong reputation in biostatistics. Pharma is also a key focus domain of the Health Campus, developed by POM Limburg, which aligns strategically with Amador’s European plans.
In the recent meeting, the Belgian Ambassador also pointed out the importance Flanders Investment and Trade as a strong partner for a company establishing itself in Flanders – we could not agree more!
“In addition to the support of the local and federal government, Belgium has become the focus of our future growth because the regulatory framework in Europe has changed in our favor,” says Xiaomin Chen.
The European Union has launched the Clinical Trial Information System (CTIS), which is implemented to harmonize clinical trial information between EU countries. Sponsors can now submit a single document to CTIS for implementation in all European member states.
Why Belgium is an interesting country for Clinical Trials
Belgium specifically is the fastest country in Europe to approve clinical trial applications (with at most a 15-day approval time for Phase I clinical trials). The country also conducts a large proportion of total European clinical trials: 13,000+ patients participate in clinical studies each year (the second highest number of EU countries), 19% of all oncological clinical studies.
Belgium has one of the most advanced medical infrastructures in the medical field, with 7 academic hospitals, 70+ hospitals, 12 internationally renowned universities, 52 member companies, and over 37,000 people and 5,300 researchers active in drug development.
“Amador intends to develop more commercial links within Belgium, as well as deepening existing ties. We’d be delighted to help other biopharmaceutical companies reach the European market, and contribute to the growth of this blossoming ecosystem," says Xiaomin Chen.
More Amador updates to follow soon!